The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-04. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Furthermore, synthetic platelet-based drug carriers can be loaded with radiosensitizers, which also improve the effectiveness of radiation therapy by increasing tumor susceptibility to radiation-induced damage. Another advantage of platelet-based treatments is their potential to overcome drug resistance—a danger of current cancer treatment options. By acting as sentinels in the bloodstream, platelets naturally take up proteins and genetic material. New treatments can leverage this for real-time biomarker detection and therapeutic monitoring. This application provides the basis for the development of liquid biopsies based on platelets to track disease progression and treatment efficacy. One of the largest constraints is the challenge of mimicking natural platelet interactions with cancer cells without accidentally stimulating cancer growth or metastasis. Natural platelets play a dual role in cancer progression in that they can help the immune system fight tumors but also facilitate cancer cell survival and metastasis by shielding circulating tumor cells from immune attack. Synthetic platelets must be carefully engineered to retain their therapeutic benefits while avoiding unintended interactions that could enhance tumor growth. Additionally, the stability, circulation time, and biodegradability of the synthetic platelets must be optimized for long-term therapeutic action without triggering unwanted immune responses.
== History == The natriuretic effects of progesterone were demonstrated in 1955, and the development of spironolactone as a synthetic antimineralocorticoid analogue of progesterone shortly followed this. Spironolactone was first synthesized in 1957, was patented between 1958 and 1961, and was first marketed, as an antimineralocorticoid, in 1959. Gynecomastia was first reported with spironolactone in 1962, and the antiandrogenic activity of the medication was first described in 1969. This shortly followed the discovery in 1967 that gynecomastia is an important and major side effect of AR antagonists. Spironolactone was first studied in the treatment of hirsutism in women in 1978. It has since become the most widely used antiandrogen for dermatological indications in women in the United States. Spironolactone was first studied as an antiandrogen in transgender women in 1986, and has since become widely adopted for this purpose as well, particularly in the United States where cyproterone acetate is not available. Early oral spironolactone tablets showed poor absorption. The formulation was eventually changed to a micronized formulation with particle sizes of less than 50 μg, which resulted in approximately 4-fold increased potency.
Prigozhin denied the allegations in a Telegram statement on 15 May, while the Kremlin described the report as a hoax. The Ukrainian air force said it destroyed 25 drones and three cruise missiles in another massive overnight attack by Russia. Seven people were killed and another 16 were injured in Russian shelling in Donetsk and Kherson oblasts. Russian-installed officials said mobile internet was temporarily suspended in occupied areas of Luhansk oblast due to increased shelling by Ukrainian troops.
Sources: en.wikipedia.org
Between 5:00pm and 6:00pm, people in England, Scotland and Wales who have signed up to the scheme are asked to use less electricity, and will be paid by their energy companies for doing so. Salisbury Crown Court in Wiltshire convicts Lawangeen Abdulrahimzai of a murder he committed in Bournemouth, Dorset, in 2022. 25 January The first ever strike by UK employees of Amazon is held. 300 staff at a Coventry warehouse stage a one-day walk out, in a dispute over pay and conditions. Lawangeen Abdulrahimzai is sentenced to life imprisonment. 26 January – Nicola Sturgeon confirms that Isla Bryson, a trans woman recently convicted of raping two women before her transition, has been moved from Cornton Vale women's prison to HMP Edinburgh men's prison, sparking debate about the Gender Recognition Reform (Scotland) Bill. 27 January Nicola Bulley disappears mysteriously whilst walking her dog beside the River Wyre. COVID-19 in the UK: Data released by the Office for National Statistics for the week ending 17 January indicate overall cases have continued to fall. In England, the estimated number of people testing positive for COVID-19 was 906,300 (roughly 1.62% of the population or 1 in 60 people). 28 January Airline Flybe (2022–2023) cancels all flights to and from the UK after going into administration. Charity Super.Mkt, billed as the UK's first multi-charity store and selling items supplied by ten charities, opens at London's Brent Cross Shopping Centre.
== Case study == In 1988, Summons et al. studied the Proterozoic Kwagunt Formation of the Chuar Group in Grand Canyon, Arizona. This sedimentary rock is 850 million years old. After performing an extraction of the rocks with organic solvents, Summons characterized the abundance of various lipid biomarkers using GC-MS/MS, as described above. Using the 412-->191 m/z transition, they identified gammacerane in the extract. Summons interpreted this signal as the diagenetic product of tetrahymanol. At the time, this lipid had only been observed in protozoa, mainly ciliates. They interpreted it as a biomarker for the existence of protozoa in the Neoproterozoic. This report is still the oldest observation of gammacerane in the rock record.
==== Therapeutic strategies ==== Several therapeutic approaches are in use or under investigation to treat the most common serpinopathy: antitrypsin deficiency. Antitrypsin augmentation therapy is approved for severe antitrypsin deficiency-related emphysema. In this therapy, antitrypsin is purified from the plasma of blood donors and administered intravenously (first marketed as Prolastin). To treat severe antitrypsin deficiency-related disease, lung and liver transplantation has proven effective. In animal models, gene targeting in induced pluripotent stem cells has been successfully used to correct an antitrypsin polymerisation defect and to restore the ability of the mammalian liver to secrete active antitrypsin. Small molecules have also been developed that block antitrypsin polymerisation in vitro.
In May 1968, Bush joined the United States Air Force and was commissioned into the Texas Air National Guard. After two years of training in active-duty service, he was assigned to Houston, flying Convair F-102s with the 147th Reconnaissance Wing out of Ellington Field Joint Reserve Base. Critics, including former Democratic National Committee Chairman Terry McAuliffe, have alleged that Bush was favorably treated due to his father's political standing as a member of the House of Representatives, citing his selection as a pilot despite his low pilot aptitude test scores and his irregular attendance. In June 2005, the Department of Defense released all the records of Bush's Texas Air National Guard service, which remain in its official archives. In late 1972 and early 1973, he drilled with the 187th Fighter Wing of the Alabama Air National Guard. He had moved to Montgomery, Alabama, to work on the unsuccessful U.S. Senate campaign of Republican Winton M. Blount. In 1972, Bush was suspended from flying for failure to take a scheduled physical exam. He was honorably discharged from the Air Force Reserve on November 21, 1974. Bush remains the most recent president to have served in the military.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.